SA520411426B1 - فيروس غدّي مزود بموصل خلايا تائية ثنائية النوعية - Google Patents

Info

Publication number

SA520411426B1

SA520411426B1 SA520411426A SA520411426A SA520411426B1 SA 520411426 B1 SA520411426 B1 SA 520411426B1 SA 520411426 A SA520411426 A SA 520411426A SA 520411426 A SA520411426 A SA 520411426A SA 520411426 B1 SA520411426 B1 SA 520411426B1

Authority

SA

Saudi Arabia

Prior art keywords

cells

sequence

cell

bispecific

fap

Prior art date

2017-08-28

Links

• Espacenet
• Global Dossier
• Discuss

• 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 129
• 210000001744 T-lymphocyte Anatomy 0.000 title abstract description 230
• 241000700605 Viruses Species 0.000 claims abstract description 291
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 290
• 238000011282 treatment Methods 0.000 claims abstract description 64
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
• 210000004027 cell Anatomy 0.000 claims description 544
• 229940126530 T cell activator Drugs 0.000 claims description 229
• 206010028980 Neoplasm Diseases 0.000 claims description 156
• 239000012190 activator Substances 0.000 claims description 150
• 201000011510 cancer Diseases 0.000 claims description 59
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 46
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
• 230000000174 oncolytic effect Effects 0.000 claims description 14
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 10
• 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 10
• 102000040430 polynucleotide Human genes 0.000 claims description 10
• 108091033319 polynucleotide Proteins 0.000 claims description 10
• 239000002157 polynucleotide Substances 0.000 claims description 10
• 210000004369 blood Anatomy 0.000 claims description 9
• 239000008280 blood Substances 0.000 claims description 9
• 239000003795 chemical substances by application Substances 0.000 claims description 6
• NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 5
• 235000013305 food Nutrition 0.000 claims description 5
• 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 4
• 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 4
• 238000003776 cleavage reaction Methods 0.000 claims description 4
• 230000002950 deficient Effects 0.000 claims description 4
• 238000013461 design Methods 0.000 claims description 4
• 239000003085 diluting agent Substances 0.000 claims description 4
• 239000003446 ligand Substances 0.000 claims description 4
• 235000002020 sage Nutrition 0.000 claims description 4
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 3
• 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 3
• 241000196324 Embryophyta Species 0.000 claims description 2
• 241000272168 Laridae Species 0.000 claims description 2
• 230000033228 biological regulation Effects 0.000 claims description 2
• 230000006378 damage Effects 0.000 claims description 2
• 241001492658 Cyanea koolauensis Species 0.000 claims 2
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
• 208000009989 Posterior Leukoencephalopathy Syndrome Diseases 0.000 claims 2
• ABYZSYDGJGVCHS-ZETCQYMHSA-N (2s)-2-acetamido-n-(4-nitrophenyl)propanamide Chemical compound CC(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 ABYZSYDGJGVCHS-ZETCQYMHSA-N 0.000 claims 1
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 1
• 241000282979 Alces alces Species 0.000 claims 1
• 241001093575 Alma Species 0.000 claims 1
• 241000428352 Amma Species 0.000 claims 1
• 102100028449 Arginine-glutamic acid dipeptide repeats protein Human genes 0.000 claims 1
• 241000271566 Aves Species 0.000 claims 1
• 101100457838 Caenorhabditis elegans mod-1 gene Proteins 0.000 claims 1
• 101100346154 Caenorhabditis elegans oma-1 gene Proteins 0.000 claims 1
• 241000511343 Chondrostoma nasus Species 0.000 claims 1
• 241001442234 Cosa Species 0.000 claims 1
• 206010011878 Deafness Diseases 0.000 claims 1
• 101100276976 Drosophila melanogaster Drak gene Proteins 0.000 claims 1
• 101100458361 Drosophila melanogaster SmydA-8 gene Proteins 0.000 claims 1
• 240000000731 Fagus sylvatica Species 0.000 claims 1
• 235000010099 Fagus sylvatica Nutrition 0.000 claims 1
• 102100035428 Formiminotransferase N-terminal subdomain-containing protein Human genes 0.000 claims 1
• 241000989913 Gunnera petaloidea Species 0.000 claims 1
• 241001417516 Haemulidae Species 0.000 claims 1
• 101001061654 Homo sapiens Arginine-glutamic acid dipeptide repeats protein Proteins 0.000 claims 1
• 101000877728 Homo sapiens Formiminotransferase N-terminal subdomain-containing protein Proteins 0.000 claims 1
• 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 claims 1
• 244000211187 Lepidium sativum Species 0.000 claims 1
• 235000007849 Lepidium sativum Nutrition 0.000 claims 1
• 101150110972 ME1 gene Proteins 0.000 claims 1
• 101000740206 Mus musculus Sal-like protein 1 Proteins 0.000 claims 1
• 101100205847 Mus musculus Srst gene Proteins 0.000 claims 1
• 241001181114 Neta Species 0.000 claims 1
• 244000061176 Nicotiana tabacum Species 0.000 claims 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
• 108010077519 Peptide Elongation Factor 2 Proteins 0.000 claims 1
• 101150107341 RERE gene Proteins 0.000 claims 1
• 241000700159 Rattus Species 0.000 claims 1
• 239000004783 Serene Substances 0.000 claims 1
• 244000269722 Thea sinensis Species 0.000 claims 1
• 102100029983 Transcriptional regulator ERG Human genes 0.000 claims 1
• 125000003275 alpha amino acid group Chemical group 0.000 claims 1
• 210000000436 anus Anatomy 0.000 claims 1
• 235000021028 berry Nutrition 0.000 claims 1
• 210000004556 brain Anatomy 0.000 claims 1
• 235000009120 camo Nutrition 0.000 claims 1
• 244000213578 camo Species 0.000 claims 1
• 210000002683 foot Anatomy 0.000 claims 1
• 108010049074 hemoglobin B Proteins 0.000 claims 1
• 108091023663 let-7 stem-loop Proteins 0.000 claims 1
• 108091063478 let-7-1 stem-loop Proteins 0.000 claims 1
• 108091049777 let-7-2 stem-loop Proteins 0.000 claims 1
• 235000013372 meat Nutrition 0.000 claims 1
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
• 238000013102 re-test Methods 0.000 claims 1
• 230000008929 regeneration Effects 0.000 claims 1
• 238000011069 regeneration method Methods 0.000 claims 1
• 239000011347 resin Substances 0.000 claims 1
• 229920005989 resin Polymers 0.000 claims 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
• 101150041594 soti gene Proteins 0.000 claims 1
• 210000003371 toe Anatomy 0.000 claims 1
• 239000011800 void material Substances 0.000 claims 1
• 239000002023 wood Substances 0.000 claims 1
• CZPRKINNVBONSF-UHFFFAOYSA-M zinc;dioxido(oxo)phosphanium Chemical compound [Zn+2].[O-][P+]([O-])=O CZPRKINNVBONSF-UHFFFAOYSA-M 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 51
• 238000009472 formulation Methods 0.000 abstract description 33
• 108700019146 Transgenes Proteins 0.000 abstract description 6
• 239000006228 supernatant Substances 0.000 description 119
• 230000014509 gene expression Effects 0.000 description 103
• 239000000523 sample Substances 0.000 description 102
• 102000004169 proteins and genes Human genes 0.000 description 70
• 230000003612 virological effect Effects 0.000 description 68
• 239000002245 particle Substances 0.000 description 61
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 57
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 57
• 108020004414 DNA Proteins 0.000 description 50
• 102000053602 DNA Human genes 0.000 description 50
• 238000001514 detection method Methods 0.000 description 49
• 210000004881 tumor cell Anatomy 0.000 description 44
• 230000006044 T cell activation Effects 0.000 description 43
• 150000001413 amino acids Chemical group 0.000 description 40
• 231100000135 cytotoxicity Toxicity 0.000 description 39
• 230000003013 cytotoxicity Effects 0.000 description 39
• 238000001994 activation Methods 0.000 description 37
• 238000000034 method Methods 0.000 description 36
• 239000002585 base Substances 0.000 description 35
• 206010003445 Ascites Diseases 0.000 description 34
• 230000004913 activation Effects 0.000 description 34
• 230000000694 effects Effects 0.000 description 34
• 238000002965 ELISA Methods 0.000 description 33
• 210000002950 fibroblast Anatomy 0.000 description 33
• 230000006870 function Effects 0.000 description 33
• 108090000695 Cytokines Proteins 0.000 description 31
• 102000004127 Cytokines Human genes 0.000 description 29
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 28
• 102000005962 receptors Human genes 0.000 description 28
• 108020003175 receptors Proteins 0.000 description 28
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
• 239000000427 antigen Substances 0.000 description 27
• 108091007433 antigens Proteins 0.000 description 27
• 102000036639 antigens Human genes 0.000 description 27
• 210000003567 ascitic fluid Anatomy 0.000 description 26
• 108020004999 messenger RNA Proteins 0.000 description 26
• 239000012530 fluid Substances 0.000 description 25
• 229950002830 enadenotucirev Drugs 0.000 description 23
• 208000015181 infectious disease Diseases 0.000 description 23
• 238000002474 experimental method Methods 0.000 description 21
• 238000004519 manufacturing process Methods 0.000 description 21
• 238000013518 transcription Methods 0.000 description 21
• 239000013612 plasmid Substances 0.000 description 20
• 230000035897 transcription Effects 0.000 description 20
• 239000011324 bead Substances 0.000 description 19
• 230000027455 binding Effects 0.000 description 19
• 101150084967 EPCAM gene Proteins 0.000 description 18
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
• 239000013068 control sample Substances 0.000 description 18
• 230000009261 transgenic effect Effects 0.000 description 18
• 201000009030 Carcinoma Diseases 0.000 description 17
• 238000002513 implantation Methods 0.000 description 17
• 239000002609 medium Substances 0.000 description 17
• 244000309459 oncolytic virus Species 0.000 description 17
• 210000002966 serum Anatomy 0.000 description 17
• 238000004458 analytical method Methods 0.000 description 16
• 238000003501 co-culture Methods 0.000 description 16
• 238000002347 injection Methods 0.000 description 16
• 239000007924 injection Substances 0.000 description 16
• 229920001184 polypeptide Polymers 0.000 description 16
• 239000013598 vector Substances 0.000 description 16
• 108091026890 Coding region Proteins 0.000 description 15
• 238000003556 assay Methods 0.000 description 15
• 239000001963 growth medium Substances 0.000 description 15
• 230000001965 increasing effect Effects 0.000 description 15
• 238000011534 incubation Methods 0.000 description 15
• 230000028327 secretion Effects 0.000 description 15
• 210000001519 tissue Anatomy 0.000 description 15
• 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 14
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 14
• 230000006798 recombination Effects 0.000 description 14
• 230000001225 therapeutic effect Effects 0.000 description 14
• 102000012804 EPCAM Human genes 0.000 description 13
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
• 101150057140 TACSTD1 gene Proteins 0.000 description 13
• 230000000120 cytopathologic effect Effects 0.000 description 13
• 239000012091 fetal bovine serum Substances 0.000 description 13
• 239000012634 fragment Substances 0.000 description 13
• 108010076504 Protein Sorting Signals Proteins 0.000 description 12
• 230000009089 cytolysis Effects 0.000 description 12
• 150000007523 nucleic acids Chemical group 0.000 description 12
• 239000000243 solution Substances 0.000 description 12
• 230000009385 viral infection Effects 0.000 description 12
• 206010027476 Metastases Diseases 0.000 description 11
• 238000001574 biopsy Methods 0.000 description 11
• 239000000872 buffer Substances 0.000 description 11
• 210000004072 lung Anatomy 0.000 description 11
• 230000003211 malignant effect Effects 0.000 description 11
• 230000001105 regulatory effect Effects 0.000 description 11
• 238000010186 staining Methods 0.000 description 11
• 102000019034 Chemokines Human genes 0.000 description 10
• 108010012236 Chemokines Proteins 0.000 description 10
• 231100000416 LDH assay Toxicity 0.000 description 10
• 230000000052 comparative effect Effects 0.000 description 10
• 238000000684 flow cytometry Methods 0.000 description 10
• 238000002843 lactate dehydrogenase assay Methods 0.000 description 10
• 210000004698 lymphocyte Anatomy 0.000 description 10
• 238000011002 quantification Methods 0.000 description 10
• 230000010076 replication Effects 0.000 description 10
• 238000012360 testing method Methods 0.000 description 10
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
• 102000006354 HLA-DR Antigens Human genes 0.000 description 9
• 108010058597 HLA-DR Antigens Proteins 0.000 description 9
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 9
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
• 238000011529 RT qPCR Methods 0.000 description 9
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 9
• 230000001506 immunosuppresive effect Effects 0.000 description 9
• 238000005215 recombination Methods 0.000 description 9
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
• 230000003213 activating effect Effects 0.000 description 8
• 239000007853 buffer solution Substances 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 238000005119 centrifugation Methods 0.000 description 8
• 230000002068 genetic effect Effects 0.000 description 8
• 239000010410 layer Substances 0.000 description 8
• 201000005296 lung carcinoma Diseases 0.000 description 8
• 239000003550 marker Substances 0.000 description 8
• 230000009401 metastasis Effects 0.000 description 8
• 230000008488 polyadenylation Effects 0.000 description 8
• 239000003380 propellant Substances 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 206010009944 Colon cancer Diseases 0.000 description 7
• 238000008157 ELISA kit Methods 0.000 description 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
• 108091006088 activator proteins Proteins 0.000 description 7
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
• 230000006037 cell lysis Effects 0.000 description 7
• 230000000875 corresponding effect Effects 0.000 description 7
• 230000009977 dual effect Effects 0.000 description 7
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
• 230000006698 induction Effects 0.000 description 7
• 238000003780 insertion Methods 0.000 description 7
• 230000037431 insertion Effects 0.000 description 7
• 210000005170 neoplastic cell Anatomy 0.000 description 7
• 239000002773 nucleotide Substances 0.000 description 7
• 125000003729 nucleotide group Chemical group 0.000 description 7
• 230000037361 pathway Effects 0.000 description 7
• 239000008188 pellet Substances 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 6
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 6
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 6
• 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 6
• 108060001084 Luciferase Proteins 0.000 description 6
• 239000000443 aerosol Substances 0.000 description 6
• 230000002238 attenuated effect Effects 0.000 description 6
• 239000006172 buffering agent Substances 0.000 description 6
• 230000015556 catabolic process Effects 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 238000006731 degradation reaction Methods 0.000 description 6
• 239000003814 drug Substances 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 239000008103 glucose Substances 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
• 210000002307 prostate Anatomy 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 5
• 102100022338 Integrin alpha-M Human genes 0.000 description 5
• 108010074328 Interferon-gamma Proteins 0.000 description 5
• 101150046193 LS gene Proteins 0.000 description 5
• 239000005089 Luciferase Substances 0.000 description 5
• 206010025538 Malignant ascites Diseases 0.000 description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 description 5
• 239000012979 RPMI medium Substances 0.000 description 5
• 230000003321 amplification Effects 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 230000000259 anti-tumor effect Effects 0.000 description 5
• 239000002246 antineoplastic agent Substances 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 230000020411 cell activation Effects 0.000 description 5
• 238000002512 chemotherapy Methods 0.000 description 5
• 239000012228 culture supernatant Substances 0.000 description 5
• 231100000263 cytotoxicity test Toxicity 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 239000003623 enhancer Substances 0.000 description 5
• 238000013213 extrapolation Methods 0.000 description 5
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
• 210000002865 immune cell Anatomy 0.000 description 5
• 230000028993 immune response Effects 0.000 description 5
• 239000007943 implant Substances 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 238000001802 infusion Methods 0.000 description 5
• 238000002955 isolation Methods 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 238000003199 nucleic acid amplification method Methods 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 238000013207 serial dilution Methods 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 238000012250 transgenic expression Methods 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• 108010029697 CD40 Ligand Proteins 0.000 description 4
• 102100032937 CD40 ligand Human genes 0.000 description 4
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• 238000012286 ELISA Assay Methods 0.000 description 4
• 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 4
• 102100037850 Interferon gamma Human genes 0.000 description 4
• 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 4
• 240000000233 Melia azedarach Species 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 108091092724 Noncoding DNA Proteins 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
• 235000015076 Shorea robusta Nutrition 0.000 description 4
• 108091081024 Start codon Proteins 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 235000011089 carbon dioxide Nutrition 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 239000013553 cell monolayer Substances 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 238000012512 characterization method Methods 0.000 description 4
• 239000012881 co-culture medium Substances 0.000 description 4
• 208000029742 colonic neoplasm Diseases 0.000 description 4
• 238000004132 cross linking Methods 0.000 description 4
• 230000001461 cytolytic effect Effects 0.000 description 4
• 231100000433 cytotoxic Toxicity 0.000 description 4
• 230000001472 cytotoxic effect Effects 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 201000010099 disease Diseases 0.000 description 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 238000011081 inoculation Methods 0.000 description 4
• 230000002147 killing effect Effects 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 230000001613 neoplastic effect Effects 0.000 description 4
• 239000013610 patient sample Substances 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 230000003248 secreting effect Effects 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 210000002536 stromal cell Anatomy 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• 230000001256 tonic effect Effects 0.000 description 4
• 210000004981 tumor-associated macrophage Anatomy 0.000 description 4
• 230000000381 tumorigenic effect Effects 0.000 description 4
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 206010005003 Bladder cancer Diseases 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 108010078791 Carrier Proteins Proteins 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
• 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 3
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
• 108091054729 IRF family Proteins 0.000 description 3
• 206010062016 Immunosuppression Diseases 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 241000713666 Lentivirus Species 0.000 description 3
• 229930195725 Mannitol Natural products 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 206010033128 Ovarian cancer Diseases 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 108091034057 RNA (poly(A)) Proteins 0.000 description 3
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
• 244000166071 Shorea robusta Species 0.000 description 3
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
• 108020005202 Viral DNA Proteins 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 230000001464 adherent effect Effects 0.000 description 3
• 230000001093 anti-cancer Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 238000012790 confirmation Methods 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 150000002016 disaccharides Chemical class 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 230000005714 functional activity Effects 0.000 description 3
• 239000007789 gas Substances 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000005469 granulation Methods 0.000 description 3
• 230000003179 granulation Effects 0.000 description 3
• 230000002519 immonomodulatory effect Effects 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 238000011532 immunohistochemical staining Methods 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 230000009545 invasion Effects 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000000594 mannitol Substances 0.000 description 3
• 235000010355 mannitol Nutrition 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 206010061289 metastatic neoplasm Diseases 0.000 description 3
• 210000000066 myeloid cell Anatomy 0.000 description 3
• 230000017074 necrotic cell death Effects 0.000 description 3
• 230000002611 ovarian Effects 0.000 description 3
• 238000004806 packaging method and process Methods 0.000 description 3
• 230000001717 pathogenic effect Effects 0.000 description 3
• 210000004303 peritoneum Anatomy 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 208000023958 prostate neoplasm Diseases 0.000 description 3
• 239000001632 sodium acetate Substances 0.000 description 3
• 235000017281 sodium acetate Nutrition 0.000 description 3
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 230000002195 synergetic effect Effects 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000006490 viral transcription Effects 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 102000008096 B7-H1 Antigen Human genes 0.000 description 2
• 108010074708 B7-H1 Antigen Proteins 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 102000011727 Caspases Human genes 0.000 description 2
• 108010076667 Caspases Proteins 0.000 description 2
• 102000003908 Cathepsin D Human genes 0.000 description 2
• 108090000258 Cathepsin D Proteins 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 238000013382 DNA quantification Methods 0.000 description 2
• 238000001712 DNA sequencing Methods 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 101150027576 FAP gene Proteins 0.000 description 2
• 101150108335 FIBL gene Proteins 0.000 description 2
• 102100027286 Fanconi anemia group C protein Human genes 0.000 description 2
• 229920001917 Ficoll Polymers 0.000 description 2
• 101710154643 Filamentous hemagglutinin Proteins 0.000 description 2
• 102000001398 Granzyme Human genes 0.000 description 2
• 108060005986 Granzyme Proteins 0.000 description 2
• 241000598171 Human adenovirus sp. Species 0.000 description 2
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
• 102000016854 Interferon Regulatory Factors Human genes 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 102000043129 MHC class I family Human genes 0.000 description 2
• 108091054437 MHC class I family Proteins 0.000 description 2
• 108010021466 Mutant Proteins Proteins 0.000 description 2
• 102000008300 Mutant Proteins Human genes 0.000 description 2
• SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 101150034459 Parpbp gene Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 208000002151 Pleural effusion Diseases 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 101150107869 Sarg gene Proteins 0.000 description 2
• 101710172711 Structural protein Proteins 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
• 108700012920 TNF Proteins 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 201000001531 bladder carcinoma Diseases 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• 210000000234 capsid Anatomy 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 238000002737 cell proliferation kit Methods 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 230000003833 cell viability Effects 0.000 description 2
• 239000012829 chemotherapy agent Substances 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• 238000012411 cloning technique Methods 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 230000002089 crippling effect Effects 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• 238000002784 cytotoxicity assay Methods 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 208000037828 epithelial carcinoma Diseases 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 108010072257 fibroblast activation protein alpha Proteins 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 238000012632 fluorescent imaging Methods 0.000 description 2
• 238000007710 freezing Methods 0.000 description 2
• 230000008014 freezing Effects 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 238000012239 gene modification Methods 0.000 description 2
• 230000005017 genetic modification Effects 0.000 description 2
• 235000013617 genetically modified food Nutrition 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 239000012216 imaging agent Substances 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
• NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
• 238000005304 joining Methods 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 238000001000 micrograph Methods 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 150000002772 monosaccharides Chemical class 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 239000002736 nonionic surfactant Substances 0.000 description 2
• 230000009437 off-target effect Effects 0.000 description 2
• 230000002246 oncogenic effect Effects 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 238000002203 pretreatment Methods 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 238000002271 resection Methods 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 229960004793 sucrose Drugs 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 150000005846 sugar alcohols Polymers 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 238000010257 thawing Methods 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 238000011287 therapeutic dose Methods 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 238000011277 treatment modality Methods 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
• 231100000588 tumorigenic Toxicity 0.000 description 2
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• -1 0045 Proteins 0.000 description 1
• YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
• ZZOXHLNZOZHWJS-LNTAAPBVSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline;[(8r,9s,10r,13s,14s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12.C1C(OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 ZZOXHLNZOZHWJS-LNTAAPBVSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical group O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
• 108020005065 3' Flanking Region Proteins 0.000 description 1
• 101150096316 5 gene Proteins 0.000 description 1
• IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 1
• 101150095992 5a gene Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000005641 Adenomyosis Diseases 0.000 description 1
• 241000701242 Adenoviridae Species 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
• 241000024188 Andala Species 0.000 description 1
• 102000003916 Arrestin Human genes 0.000 description 1
• 108090000328 Arrestin Proteins 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 241000588807 Bordetella Species 0.000 description 1
• 241000588832 Bordetella pertussis Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 108010061300 CXCR3 Receptors Proteins 0.000 description 1
• 102000011963 CXCR3 Receptors Human genes 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010048832 Colon adenoma Diseases 0.000 description 1
• PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 238000007400 DNA extraction Methods 0.000 description 1
• 108010069941 DNA receptor Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 241000539679 Defiwi virus Species 0.000 description 1
• 102100036727 Deformed epidermal autoregulatory factor 1 homolog Human genes 0.000 description 1
• 241001269524 Dura Species 0.000 description 1
• 241000539685 Egaro virus Species 0.000 description 1
• 102100038083 Endosialin Human genes 0.000 description 1
• 101710144543 Endosialin Proteins 0.000 description 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical class CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 102000004961 Furin Human genes 0.000 description 1
• 108090001126 Furin Proteins 0.000 description 1
• 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
• 102000013382 Gelatinases Human genes 0.000 description 1
• 108010026132 Gelatinases Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
• 208000031448 Genomic Instability Diseases 0.000 description 1
• 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 206010019695 Hepatic neoplasm Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000777387 Homo sapiens C-C motif chemokine 3 Proteins 0.000 description 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
• 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 1
• 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 description 1
• 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
• 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
• 101000699762 Homo sapiens RNA 3'-terminal phosphate cyclase Proteins 0.000 description 1
• 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
• 101000847066 Homo sapiens Translin-associated protein X Proteins 0.000 description 1
• 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 102100030482 Hypoxia-inducible factor 3-alpha Human genes 0.000 description 1
• 101710083143 Hypoxia-inducible factor 3-alpha Proteins 0.000 description 1
• 102000043138 IRF family Human genes 0.000 description 1
• 101150032643 IVa2 gene Proteins 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 208000000785 Invasive Pulmonary Aspergillosis Diseases 0.000 description 1
• 108010025815 Kanamycin Kinase Proteins 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• 241000283986 Lepus Species 0.000 description 1
• 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 1
• 241000234435 Lilium Species 0.000 description 1
• 239000012097 Lipofectamine 2000 Substances 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 238000000719 MTS assay Methods 0.000 description 1
• 231100000070 MTS assay Toxicity 0.000 description 1
• 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 108091027974 Mature messenger RNA Proteins 0.000 description 1
• 241000252067 Megalops atlanticus Species 0.000 description 1
• 101710154541 Modulator protein Proteins 0.000 description 1
• 229930191564 Monensin Natural products 0.000 description 1
• GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
• 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
• 102000004459 Nitroreductase Human genes 0.000 description 1
• 102000011931 Nucleoproteins Human genes 0.000 description 1
• 108010061100 Nucleoproteins Proteins 0.000 description 1
• 239000012124 Opti-MEM Substances 0.000 description 1
• 244000218514 Opuntia robusta Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 101710173835 Penton protein Proteins 0.000 description 1
• 201000005702 Pertussis Diseases 0.000 description 1
• 241000042032 Petrocephalus catostoma Species 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 241001377010 Pila Species 0.000 description 1
• 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
• 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 108010076039 Polyproteins Proteins 0.000 description 1
• 229920001219 Polysorbate 40 Polymers 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102100029143 RNA 3'-terminal phosphate cyclase Human genes 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 208000035415 Reinfection Diseases 0.000 description 1
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
• 102100032834 Translin-associated protein X Human genes 0.000 description 1
• 239000007997 Tricine buffer Substances 0.000 description 1
• 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 108700005077 Viral Genes Proteins 0.000 description 1
• 108010087302 Viral Structural Proteins Proteins 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 231100000230 acceptable toxicity Toxicity 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 108700010877 adenoviridae proteins Proteins 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 229960003942 amphotericin b Drugs 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 238000011394 anticancer treatment Methods 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 238000010420 art technique Methods 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 101150036080 at gene Proteins 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000001851 biosynthetic effect Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
• JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
• SYRIRLOOSKFSFC-UHFFFAOYSA-N butane Chemical compound CCCC.CCCC SYRIRLOOSKFSFC-UHFFFAOYSA-N 0.000 description 1
• 239000001273 butane Substances 0.000 description 1
• 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
• 235000015155 buttermilk Nutrition 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 230000005880 cancer cell killing Effects 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 206010061592 cardiac fibrillation Diseases 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000006652 catabolic pathway Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 210000003850 cellular structure Anatomy 0.000 description 1
• JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
• SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 210000004081 cilia Anatomy 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 230000003021 clonogenic effect Effects 0.000 description 1
• 230000006690 co-activation Effects 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000003583 cytomorphological effect Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 239000000645 desinfectant Substances 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 235000013681 dietary sucrose Nutrition 0.000 description 1
• 235000019621 digestibility Nutrition 0.000 description 1
• KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• XSIUFRZYAOLCQE-UHFFFAOYSA-L dimagnesium;dichloride Chemical compound [Mg+2].[Mg+2].[Cl-].[Cl-] XSIUFRZYAOLCQE-UHFFFAOYSA-L 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 230000013931 endocrine signaling Effects 0.000 description 1
• 230000005966 endogenous activation Effects 0.000 description 1
• 201000009274 endometriosis of uterus Diseases 0.000 description 1
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 108060002566 ephrin Proteins 0.000 description 1
• 102000012803 ephrin Human genes 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 230000001973 epigenetic effect Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 210000000416 exudates and transudate Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 230000002600 fibrillogenic effect Effects 0.000 description 1
• 230000020764 fibrinolysis Effects 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 108091006047 fluorescent proteins Proteins 0.000 description 1
• 102000034287 fluorescent proteins Human genes 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
• 229960002963 ganciclovir Drugs 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 108091008053 gene clusters Proteins 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 150000008282 halocarbons Chemical class 0.000 description 1
• 125000001475 halogen functional group Chemical group 0.000 description 1
• 150000005826 halohydrocarbons Chemical class 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 102000043726 human CCL3 Human genes 0.000 description 1
• 102000046949 human MSC Human genes 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• 229940091204 imlygic Drugs 0.000 description 1
• 230000005934 immune activation Effects 0.000 description 1
• 230000008102 immune modulation Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 230000014828 interferon-gamma production Effects 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 239000001282 iso-butane Substances 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 239000010977 jade Substances 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 229960005358 monensin Drugs 0.000 description 1
• GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
• OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 108020001162 nitroreductase Proteins 0.000 description 1
• 231100001083 no cytotoxicity Toxicity 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 210000003924 normoblast Anatomy 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 150000002482 oligosaccharides Polymers 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000008775 paternal effect Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 108010021711 pertactin Proteins 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000005191 phase separation Methods 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 210000004910 pleural fluid Anatomy 0.000 description 1
• 230000010287 polarization Effects 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
• 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229940101027 polysorbate 40 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 230000015243 positive regulation of T cell cytokine production Effects 0.000 description 1
• 238000012809 post-inoculation Methods 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000036316 preload Effects 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 239000006041 probiotic Substances 0.000 description 1
• 235000018291 probiotics Nutrition 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 210000005267 prostate cell Anatomy 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 235000008001 rakum palm Nutrition 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 108010054624 red fluorescent protein Proteins 0.000 description 1
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
• 201000010174 renal carcinoma Diseases 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 102220080600 rs797046116 Human genes 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 108700021652 sis Genes Proteins 0.000 description 1
• 239000010802 sludge Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 238000009987 spinning Methods 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 239000012089 stop solution Substances 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000013595 supernatant sample Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 231100000057 systemic toxicity Toxicity 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 238000002723 toxicity assay Methods 0.000 description 1
• 230000005758 transcription activity Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000006648 viral gene expression Effects 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1